Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs*

Scandinavian Cardiovascular Journal

Volumn 51, Issue 1, 2017, Pages 8-14

  Ekström, Kathrine ^a,b   Dalsgaard, Morten ^c   Iversen, Kasper ^a   Pedersen Bjergaard, Ulrik ^a   Vejlstrup, Niels ^c   Diemar, Sarah Seberg ^a,b   Idorn, Manja ^d   Thorsteinsson, Birger ^a,b   Engstrøm, Thomas ^c  

^a HILLERØD HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardioprotection; ischemia reperfusion injury; ischemic postconditioning; liraglutide

Indexed keywords

LIRAGLUTIDE; INCRETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; ISCHEMIC POSTCONDITIONING; LANDRACE PIG; MORTALITY RATE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; ADVERSE EFFECTS; ANIMAL; BALLOON OCCLUSION; CARDIAC MUSCLE; COMPARATIVE STUDY; DISEASE MODEL; MULTIMODALITY CANCER THERAPY; MYOCARDIAL INFARCTION; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PIG; PROCEDURES; REPERFUSION INJURY; VENTRICULAR FIBRILLATION;

ANIMALS; BALLOON OCCLUSION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; INCRETINS; ISCHEMIC POSTCONDITIONING; LIRAGLUTIDE; MYOCARDIAL INFARCTION; MYOCARDIUM; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; SWINE; VENTRICULAR FIBRILLATION;

EID: 84978970979     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017431.2016.1197417     Document Type: Article

References (22)

1. Sharma V, Bell RM, Yellon DM., Targeting reperfusion injury in acute myocardial infarction:a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 2012;13:1153–1175.
2. Yellon DM, Hausenloy DJ., Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135.
3. Kristensen J, Mortensen UM, Schmidt M, et al. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord. 2009;9:31.
4. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–983.
5. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146–151.
6. Bose AK, Mocanu MM, Carr RD, et al. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther. 2005;19:9–11.
7. Kavianipour M, Ehlers MR, Malmberg K, et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24:569–578.
8. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2011;33:1491–1499.
9. Sonne DP, Engstrom T, Treiman M., Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243–249.
10. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501–510.
11. Ussher JR, Drucker DJ., Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187–215.
12. Wohlfart P, Linz W, Hubschle T, et al. Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies. J Transl Med. 2013;11:84.
13. Ravassa S, Zudaire A, Diez J., GLP-1 and cardioprotection:from bench to bedside. Cardiovasc Res. 2012;94:316–323.
14. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury:where do we stand? Position paper from the working group of cellular biology of the heart of the European society of cardiology. Cardiovasc Res. 2010;87:406–423.
15. Skyschally A, Walter B, Schultz Hansen R, et al. The antiarrhythmic dipeptide ZP1609 (danegaptide) when given at reperfusion reduces myocardial infarct size in pigs. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:383–391.
16. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion:comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–H588.
17. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005;112:2143–2148.
18. Thuny F, Lairez O, Roubille F, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175–2181.
19. Lonborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv. 2010;3:34–41.
20. Suzuki Y, Lyons JK, Yeung AC, et al. In vivo porcine model of reperfused myocardial infarction:in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc Interv. 2008;71:100–107.
21. Diemar SS, Sejling AS, Iversen KK, et al. Influence of acute glycaemic level on measures of myocardial infarction in non-diabetic pigs. Scand Cardiovasc J. 2015;49:376–382.
22. Busch SV, Halladin NL, Jensen SE, et al. Closed-chest porcine model is superior in intervention studies of ischaemia reperfusion injury. Ugeskr Laeger. 2012;174:1807–1810.